Accessibility Menu
Skye Bioscience logo

Skye Bioscience(NASDAQ) SKYE

Market Cap$22.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-98%
1 Year-84%
1 Month-4%
$0.62
-4.74%
-0.03Today
Skye Bioscience last closing stock price
MetricPriceDate
Last closeUSD 0.652026-07-24
Skye Bioscience stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.4%USD 0.652026-07-17
1 month-3.99%USD 0.682026-06-24
3 month-32.79%USD 0.972026-04-24
Year to date-13.05%USD 0.752025-12-31
1 year-83.74%USD 4.012025-07-24
3 year-91.31%USD 7.502023-07-25
5 year-98.2%USD 36.252021-07-23
Since inception-99.97%USD 2,500.002014-11-26

Skye Bioscience Financials at a Glance

Market Cap

$22.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$57.33M

EPS (TTM)

-$1.45

P/E Ratio

-0.45

Dividend

$0.00

Beta (Volatility)

0.65 (Low)

Price

$0.62

Volume

133,316.35

Open

$0.65

Previous Close

$0.62

Daily Range

$0.62 - $0.66

52-Week Range

$0.57 - $4.99

Estimated Earnings Date

Aug 6, 2026

SKYE News

Foolcom-Featured.png

Skye (SKYE) Q2 R&D Soars 249% No Revenue

Motley Fool Markets TeamAug 7, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Skye Bioscience

Skye Bioscience develops new medicines for obesity and related health issues. Its main drug aims to help people lose weight safely. The company focuses on treatments that avoid common side effects of older drugs.

What’s in the Skye Medicine Cabinet?

  • Nimacimab: Antibody drug in clinical trials for obesity and overweight; not yet generating any revenue but targets people needing weight management solutions.
  • SBI-100: Former eye disease drug candidate; program ended in 2024, no longer a focus.
  • SBI-200: Early-stage research for eye diseases like dry eye and diabetic retinopathy; not a current priority.
  • Drug Delivery Partnerships: Collaboration with Halozyme to improve nimacimab’s delivery method for easier patient use.

Growth Spurts and Strategic Moves

  • Acquired Bird Rock Bio in August 2023, gaining nimacimab and expanding into obesity treatment.
  • Signed a global license with Halozyme in December 2025 for advanced drug delivery technology.
  • Raised $83.6 million in new funding in early 2024 to support clinical trials and operations.
  • Uplisted to the Nasdaq Global Market in April 2024, increasing visibility among investors.
  • Ended development of SBI-100 for eye diseases in 2024 to focus on metabolic disorders.

Why Skye’s Approach Stands Out

Skye’s main drug, nimacimab, targets obesity without affecting the brain, aiming to reduce side effects. The company’s once-monthly dosing could improve patient convenience. Its patent portfolio covers nimacimab’s use through at least 2035, supporting its competitive position.

Five Things You Need to Know

  • No revenue in 2025, 2024, or 2023; company is pre-commercial.
  • Net loss was $55.9 million in 2025, up 110% from 2024.
  • Research and development expenses rose 127% to $42.4 million in 2025.
  • Cash position was $25.7 million at December 31, 2025.
  • Auditor raised doubt about ability to operate beyond Q4 2026 without new funding.

Bottom Line

Skye has shifted from eye disease research to focus on obesity treatments. The company remains in early stages, with no product sales and ongoing funding needs.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

12

CEO

Punit S. Dhillon

Website

skyebioscience.com

Headquarters

San Diego, CA 92130, US

SKYE Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-217.27%

Return on Capital

-286.55%

Return on Assets

-295.27%

Earnings Yield

-2.22%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$22.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

35.14M

Volume

133.32K

Avg. Volume

163.49K

Financials (TTM)

Gross Profit

-$172.89K

Operating Income

-$59.08M

EBITDA

-$56.61M

Operating Cash Flow

-$42.43M

Capital Expenditure

-$14.00

Free Cash Flow

-$42.43M

Cash & ST Invst.

$17.11M

Total Debt

$311.32K

Skye Bioscience Performance Analysis

Skye Bioscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Skye Bioscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Skye Bioscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -8.7767.4%
20232023-12-31USD -5.37-38.7%
20242024-12-31USD -0.73-86.4%
20252025-12-31USD -1.4193.7%
Skye Bioscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-57.1%
Q32025-09-3027.3%
Q42025-12-31-12.5%
Q12026-03-3111.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$172.89K

N/A

Gross Margin

0.00%

N/A

Market Cap

$22.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.91M

N/A

Employees

12

N/A

Net Income

-$12.51M

-12.7%

EBITDA

-$12.33M

-12.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$17.11M

-71.1%

Total Debt

$311.32K

-24.5%

Accounts Receivable

$9.53K

+49.1%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$311.32K

+65.0%

Return on Assets

-2.95%

N/A

Return on Invested Capital

-6.56%

N/A

Free Cash Flow

-$8.56M

+99.9%

Operating Cash Flow

-$8.56M

+99.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BRNSBarinthus Biotherapeutics plc
$0.60-0.17%
ALGSAligos Therapeutics, Inc.
$4.08+0.00%
PDSBPDS Biotechnology Corporation
$0.69+1.66%
LVTXLAVA Therapeutics N.V.
$1.74-3.87%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About SKYE

What is the current price of Skye Bioscience?

Skye Bioscience is trading at $0.62 per share.

What is the 52-week range for Skye Bioscience?

Over the past 52 weeks, Skye Bioscience has traded between $0.57 and $4.99.

How much debt does Skye Bioscience have?

As of the most recent reporting period, Skye Bioscience reported total debt of $311.32K.

How much cash does Skye Bioscience have on hand?

Skye Bioscience reported $8.15M in cash and cash equivalents in its most recent financial results.

What is Skye Bioscience’s dividend yield?

Skye Bioscience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services